Kane Biotech Inc. (TSXV:KNE)
| Market Cap | 6.15M -17.8% |
| Revenue (ttm) | 38.72K -97.9% |
| Net Income | -2.70M |
| EPS | -0.02 |
| Shares Out | 205.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Open | 0.0300 |
| Previous Close | 0.0300 |
| Day's Range | 0.0300 - 0.0300 |
| 52-Week Range | 0.0150 - 0.0500 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 27, 2026 |
About Kane Biotech
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio inclu... [Read more]
Financial Performance
Financial StatementsNews
Kane Biotech Transcript: Investor update
The company has refocused on wound care, expanding its revyve product platform and distribution network, with clinical evidence supporting efficacy in challenging wounds. Commercial momentum is building, supported by new partnerships, a planned capital raise, and targeted expansion into Europe and military channels.
Kane Biotech Press release: Investor update
Kane Biotech issued a press release on September 16, 2026, disclosing material business information to investors.
Kane Biotech to Host Commercial Update Webcast on September 16
Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane’s commercial progress, clinical relevance and operational priorities WINNIP...
Kane Biotech to Host Commercial Update Webcast on September 16
Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities Board ...
Kane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.
Agreement broadens access to revyve® advanced wound care products through an established Canadian medical supply distributor WINNIPEG, Manitoba, Sept. 02, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TS...
Kane Biotech Q2 Net Loss Expands; Revenue Declines
(RTTNews) - Kane Biotech Inc. (KNE.V), which develops wound care treatments, announced financial results for the second quarter of 2026, reflecting a wider net loss and revenue decline as the company ...
Kane Biotech Announces Second Quarter 2026 Financial Results
WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results. Second Quarter 2...
Kane Biotech Announces Second Quarter 2026 Financial Results
WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.
Kane Biotech Earnings release: Q2 2026
Kane Biotech released its Q2 2026 earnings on August 27, 2026, summarizing the period's financial results.
Kane Biotech Registration statement: Q2 2026
Kane Biotech filed a registration statement on August 27, 2026, providing details about a securities offering with the SEC.
Kane Biotech Registration statement: Q2 2026
Kane Biotech filed a registration statement on August 27, 2026, providing details about a securities offering with the SEC.
Kane Biotech Presents Revyve Research For Military Wound Care Applications
(RTTNews) - Kane Biotech Inc. (KNE.V) announced that research on its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium, highlighting its potenti...
Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium
Presentation addressed potential applications in prolonged field care and military wound management settings WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Co...
Kane Biotech Announces Engagement of DNA Advisors
DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, a...
Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (th...
Kane Biotech Announces Grant of Stock Options
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 29, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the ...
Kane Biotech Announces First Quarter 2026 Financial Results
WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.
Kane Biotech Registration statement: Q1 2026
Kane Biotech filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
Kane Biotech Registration statement: Q1 2026
Kane Biotech filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
Kane Biotech Earnings release: Q1 2026
Kane Biotech released its Q1 2026 earnings on May 28, 2026, summarizing the period's financial results.
Kane Biotech Slides: Investor presentation
Kane Biotech has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Kane Biotech Announces the Oversubscription and Closing of Private Placement Offering
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 26, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane...
Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress
Case study presented highlighted clinical experience with revyve® in complex wound care Case study presented highlighted clinical experience with revyve® in complex wound care
Kane Biotech Announces New Private Placement Offering
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the ...
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its fourth quarter and full year 2025 financial results.